atrasentan
atrasentan: sourced relationships with 2 companies · 5 clinical trials tracked · 1 FDA decision.
atrasentan evidence translation
What we can confirm
1 FDA record · 5 tracked trials
What it means
What to watch
Prepared research question
What is verified about atrasentan, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| CHINOOK THERAPEUTICS, INC. (KDNY) IgA nephropathy (IgAN) and proteinuric glomerular diseases | Phase 3 |
| Novartis AG (NVS) Reported 2025-04-02 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (5)
A Phase IIIb, Multi-center, Two-arm, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Zigakibart and Atrasentan Versus Zigakibart and Placebo in Patients With Primary IgA Nephropathy
Primary endpoint: Change in proteinuria from Baseline to Week 36, based on 24 hour urine collection
A Multicenter, Single Arm, Open Label, Pilot Study to Assess the Effect of Atrasentan Alongside Supportive Care on Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy (IgAN)
Primary endpoint: Proportion of participants achieving improvement in at least one component of the composite kidney mpMRI endpoint at Month 6
A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)
Primary endpoint: Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 12
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
Primary endpoint: Change in proteinuria for IgAN, FSGS, and Alport syndrome patients receiving 0.75 mg atrasentan QD
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Primary endpoint: Double-blind period: Change in proteinuria
Frequently asked questions
Which companies have sourced relationships with atrasentan?
atrasentan has dated SEC/FDA relationship records for CHINOOK THERAPEUTICS, INC., Novartis AG.
How many clinical trials involve atrasentan?
BioSniper tracks 5 clinical trials involving atrasentan.
What is atrasentan's latest FDA decision?
The most recent tracked FDA decision for atrasentan is Approval, dated April 2, 2025.